Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer

BMC Clinical Pathology

Caj Haglund⁴  Johanna Louhimo²  Timo Sorsa¹  Mikael Lundin³  Nina Linder³  Jaana Hagström⁴  Selja Koskensalo² 

[1] Institute of Dentistry, University of Helsinki and Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, Helsinki, Finland;Department of Surgery, Helsinki University Central Hospital, P.O. Box 440, 00029 HUS, Helsinki, Finland;Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, FIN-00014 HY, Finland;Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, FIN-00014 HY, Finland

关键词: Immunohistochemistry;    Prognosis;    Colorectal cancer;    MMP-9;    MMP-8;    MMP-2;   

Others  :  1085201
DOI  :  10.1186/1472-6890-12-24

 received in 2012-06-07, accepted in 2012-11-29,  发布年份 2012

【 摘 要 】

Background

Matrix metalloproteinases (MMPs) play a role in cancer progression by degrading extracellular matrix and basement membranes, assisting in tumour neovascularization and in supporting immune response in cancer.

Methods

We studied the prognostic value of immunohistochemical expression of MMP-2, MMP-8, and MMP-9 in a series of 619 colorectal cancer patients using tissue microarray specimens.

Results

Of the samples, 56% were positive for MMP-2, 78% for MMP-8, and 60% for MMP-9. MMP-9 associated with low WHO grade (p < 0.001). In univariate analysis of Dukes’ B tumours, MMP-9 negativity associated with poor survival (p = 0.018), and MMP-9 positivity was an independent prognostic marker in multivariate analysis of these tumours (p = 0.034).

Conclusion

Negative MMP-9 expression can predict poor prognosis in Dukes’ B colorectal tumours and may prove useful for identifying patients, who should be offered adjuvant treatment.

【 授权许可】

   
2012 Koskensalo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Compton CC: Pathology report in colon cancer: what is prognostically important? Dig Dis 1999, 17(2):67-79.
• [3]Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124(7):979-994.
• [4]Yang Z, Wang L, Kang L, Xiang J, Peng J, Cui J, Huang Y, Wang J: Clinicopathologic characteristics and outcomes of patients with obstructive colorectal cancer. J Gastrointest Surg 2011, 15(7):1213-1222.
• [5]Anwar MA, D’Souza F, Coulter R, Memon B, Khan IM, Memon MA: Outcome of acutely perforated colorectal cancers: experience of a single district general hospital. Surg Oncol 2006, 15(2):91-96.
• [6]Crispino P, De Toma G, Ciardi A, Bella A, Rivera M, Cavallaro G, Polistena A, Fornari F, Unim H, Pica R, Cassieri C, Mingazzini PL, Paoluzi P: Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication. Cancer Invest 2008, 26(4):419-425.
• [7]Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
• [8]Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997, 182(3):318-324.
• [9]Coussens LM, Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 1996, 3(11):895-904.
• [10]Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG: The collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987, 262(21):10048-10052.
• [11]Matsuyama Y, Takao S, Aikou T: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002, 80(2):105-110.
• [12]Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N, Talieri M: Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 2001, 22(6):383-389.
• [13]Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M: Prognostic significance of matrix metalloproteinases-1, -2, -7 and −13 and tissue inhibitors of metalloproteinases-1, -2, -3 and −4 in colorectal cancer. Int J Cancer 2007, 121(4):714-723.
• [14]Zeng ZS, Huang Y, Cohen AM, Guillem JG: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996, 14(12):3133-3140.
• [15]Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V: Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997, 17(3):158-168.
• [16]Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, Specterman S, de Kier Joffe EB, Pallotta MG, Puricelli LI, Lastiri J: Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 2006, 93(2):151-160.
• [17]Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, Lopez-Otin C: Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 2008, 68(8):2755-2763.
• [18]Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D: Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 2004, 64(5):1687-1694.
• [19]Davis NC, Evans EB, Cohen JR, Theile DE: Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes’ system. Dis Colon Rectum 1984, 27(11):707-713.
• [20]Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT: Effects of tetracyclines on neutrophil, gingival and salivary collagenase. A functional and western-blot assessment with special reference to their cellular sources in periodontal disease. Ann N Y Acad Sci 1994, 732:112-131.
• [21]Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S, Syrjanen K, Pyrhonen S: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer 2009, 40(3–4):91-97.
• [22]Koumura H, Sugiyama Y, Kunieda K, Saji S: Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer. Gan To Kagaku Ryoho 1997, 24(Suppl 2):324-331.
• [23]Jensen SA, Vainer B, Bartels A, Brunner N, Sorensen JB: Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells–associations with histopathology and patients outcome. Eur J Cancer 2010, 46(18):3233-3242.
• [24]Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993, 85(7):574-578.
• [25]Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T: Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004, 10(9):3110-3116.
• [26]Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996, 74(3):413-417.
• [27]Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M: Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001, 84(11):1488-1496.
• [28]Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997, 88(1):72-81.
• [29]Saito K, Takeha S, Shiba K, Matsuno S, Sorsa T, Nagura H, Ohtani H: Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 2000, 86(1):24-29.
• [30]Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10:657-662.
• [31]Masuda H, Aoki H: Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer. Dis Colon Rectum 1999, 42(3):393-397.
• [32]Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T: Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999, 75(1):91-98.
• [33]Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003, 89(7):1270-1275.
• [34]Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A: Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 2008, 31(1):55-63.